TNFRSF1A and rheumatoid arthritis: Taken together, these results indicate that Th1 and Th17 cells from RA patients exhibit an altered expression pattern of TNFR1 and TNFR2 compared to healthy subjects, and that therapeutic administration of adalimumab to these patients does not restore the levels of TNF-α receptors on the aforementioned cell populations.